The combination of pimozide and the MAST1 inhibitor lestaurtinib markedly decreases MAST1 expression and the phosphorylation of MEK1 and ERK in cancer cells, enhancing their sensitivity to cisplatin [43]. Here, MAST1 is linked to cancer.